Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes

Babjuk, 2022, European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ), Eur Urol, 81, 75, 10.1016/j.eururo.2021.08.010 Chang, 2016, Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline, J Urol, 196, 1021, 10.1016/j.juro.2016.06.049 Tan, 2016, Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia, Cancer Treat Rev, 47, 22, 10.1016/j.ctrv.2016.05.002 US Department of Health and Human Services Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. 2018. https://www.fda.gov/media/101468/download#:∼:text=For%20the%20purposes%20of%20this,completion%20of%20adequate%20BCG%20therapy. Balar, 2021, Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study, Lancet Oncol, 22, 919, 10.1016/S1470-2045(21)00147-9 Boorjian, 2021, Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial, Lancet Oncol, 22, 107, 10.1016/S1470-2045(20)30540-4 Tan, 2021, Is delay to radical cystectomy following BCG failure oncologically safe?, Nat Rev Urol, 18, 323, 10.1038/s41585-021-00457-1 Kamat, 2016, Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group, J Clin Oncol, 34, 1935, 10.1200/JCO.2015.64.4070 The University of Texas MD Anderson Cancer Center. Urothelial carcinoma of bladder and upper tract treatment algorithm. 2022. Li, 2022, CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG), J Clin Oncol, 40, 4597, 10.1200/JCO.2022.40.16_suppl.4597 Chamie, 2022, Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC), J Clin Oncol, 40, 4508, 10.1200/JCO.2022.40.16_suppl.4508 Steinberg, 2020, Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer, J Urol, 203, 902, 10.1097/JU.0000000000000688 Haas, 2016, The timing of radical cystectomy for bacillus Calmette-Guerin failure: comparison of outcomes and risk factors for prognosis, J Urol, 195, 1704, 10.1016/j.juro.2016.01.087 Lammers, 2011, Smoking status is a risk factor for recurrence after transurethral resection of non–muscle-invasive bladder cancer, Eur Urol, 60, 713, 10.1016/j.eururo.2011.07.010 Wyszynski, 2014, Body mass and smoking are modifiable risk factors for recurrent bladder cancer, Cancer, 120, 408, 10.1002/cncr.28394